caffeine has been researched along with Parkinsonian Disorders in 30 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum." | 7.96 | Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 7.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| "The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum." | 3.96 | Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 3.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| "Caffeine is a nonselective adenosine receptor antagonist that blocks 2 major types of adenosine receptors, A1AR and A2AAR, in the brain." | 2.44 | Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. ( Ramkumar, V; Toth, LA; Xie, X, 2007) |
| "3." | 2.41 | The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. ( Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S, 2002) |
| "Caffeine, which is a known neuroprotectant, can potentially act as an adjunct to minimise adverse effects of L-DOPA." | 1.56 | Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic ( Manalo, RVM; Medina, PMB, 2020) |
| " Parkinson's model was developed by chronic administration of a pesticide rotenone that inhibits mitochondrial complex I resulting in generation of reactive oxygen species." | 1.51 | Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. ( Bandookwala, M; Khairnar, A; Sahu, AK; Sengupta, P; Sharma, M; Thakkar, D, 2019) |
| "Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine." | 1.42 | Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015) |
| "Caffeine-treated samples showed improved binding to phospholipids, a property likely to be important in cellular functioning of α-synuclein." | 1.42 | Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease. ( Kardani, J; Roy, I, 2015) |
| "In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine." | 1.39 | Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. ( Acuña-Lizama, MM; Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL, 2013) |
| "Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)." | 1.35 | Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009) |
| "(1) Caffeine treatment produced a dose-dependent attenuation of MPTP-induced striatal dopamine loss in both young and retired breeder (RB) male, but not female, mice." | 1.33 | Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Ascherio, A; Brown-Jermyn, D; Chen, JF; Dluzen, DE; Schwarzschild, MA; Xu, K; Xu, Y, 2006) |
| " Acute and chronic administration of CSC was studied to evaluate the possible reversion or prevention of these levodopa effects." | 1.31 | Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. ( Bonastre, M; Bové, J; Marin, C; Tolosa, E, 2002) |
| "When caffeine was removed, tolerance to bromocriptine effects was observed for 1 day only, while no tolerance was observed to pergolide." | 1.31 | Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats. ( Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reichmann, H | 1 |
| Csoti, I | 1 |
| Koschel, J | 1 |
| Lorenzl, S | 1 |
| Schrader, C | 1 |
| Winkler, J | 1 |
| Wüllner, U | 1 |
| Bandookwala, M | 1 |
| Sahu, AK | 1 |
| Thakkar, D | 1 |
| Sharma, M | 1 |
| Khairnar, A | 1 |
| Sengupta, P | 1 |
| Takeshige-Amano, H | 1 |
| Saiki, S | 1 |
| Fujimaki, M | 1 |
| Ueno, SI | 1 |
| Li, Y | 1 |
| Hatano, T | 1 |
| Ishikawa, KI | 1 |
| Oji, Y | 1 |
| Mori, A | 1 |
| Okuzumi, A | 1 |
| Tsunemi, T | 1 |
| Daida, K | 1 |
| Ishiguro, Y | 1 |
| Imamichi, Y | 1 |
| Nanmo, H | 1 |
| Nojiri, S | 1 |
| Funayama, M | 1 |
| Hattori, N | 1 |
| Manalo, RVM | 1 |
| Medina, PMB | 1 |
| Kasture, SB | 1 |
| Gaikar, M | 1 |
| Kasture, V | 1 |
| Arote, S | 1 |
| Salve, B | 1 |
| Rosas, M | 1 |
| Cotti, E | 1 |
| Acquas, E | 1 |
| Fernández-Dueñas, V | 1 |
| Gómez-Soler, M | 1 |
| López-Cano, M | 1 |
| Taura, JJ | 1 |
| Ledent, C | 1 |
| Watanabe, M | 1 |
| Jacobson, KA | 1 |
| Vilardaga, JP | 1 |
| Ciruela, F | 1 |
| Kardani, J | 1 |
| Roy, I | 1 |
| Singhal, NK | 1 |
| Agarwal, S | 1 |
| Bhatnagar, P | 1 |
| Tiwari, MN | 1 |
| Tiwari, SK | 1 |
| Srivastava, G | 1 |
| Kumar, P | 1 |
| Brashket, S | 1 |
| Patel, DK | 2 |
| Chaturvedi, RK | 1 |
| Singh, MP | 2 |
| Gupta, KC | 1 |
| Alisky, J | 1 |
| Luthra, PM | 1 |
| Barodia, SK | 1 |
| Raghubir, R | 1 |
| Singh, S | 1 |
| Singh, K | 1 |
| Gupta, SP | 1 |
| Singh, VK | 1 |
| Singh, RK | 1 |
| Trevitt, J | 1 |
| Kawa, K | 1 |
| Jalali, A | 1 |
| Larsen, C | 1 |
| Nobre, HV | 1 |
| Cunha, GM | 1 |
| de Vasconcelos, LM | 1 |
| Magalhães, HI | 1 |
| Oliveira Neto, RN | 1 |
| Maia, FD | 1 |
| de Moraes, MO | 1 |
| Leal, LK | 1 |
| Viana, GS | 1 |
| Bata-García, JL | 2 |
| Tun-Cobá, L | 1 |
| Alvarez-Cervera, FJ | 2 |
| Villanueva-Toledo, JR | 1 |
| Heredia-López, FJ | 1 |
| Góngora-Alfaro, JL | 2 |
| Huang, YX | 1 |
| Luo, WF | 1 |
| Li, D | 1 |
| Hu, WD | 1 |
| Liu, CF | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Acuña-Lizama, MM | 1 |
| Bové, J | 2 |
| Marin, C | 2 |
| Bonastre, M | 1 |
| Tolosa, E | 1 |
| Da Cunha, C | 2 |
| Angelucci, ME | 1 |
| Canteras, NS | 1 |
| Wonnacott, S | 1 |
| Takahashi, RN | 2 |
| Schwarzschild, MA | 4 |
| Xu, K | 4 |
| Oztas, E | 1 |
| Petzer, JP | 2 |
| Castagnoli, K | 2 |
| Castagnoli, N | 2 |
| Chen, JF | 4 |
| El Yacoubi, M | 1 |
| Costentin, J | 1 |
| Vaugeois, JM | 1 |
| Ren, J | 1 |
| Porter, JE | 1 |
| Wold, LE | 1 |
| Aberle, NS | 1 |
| Muralikrishnan, D | 1 |
| Haselton, JR | 1 |
| Ulanowska, K | 1 |
| Piosik, J | 1 |
| Gwizdek-Wiśniewska, A | 1 |
| We Grzyn, G | 1 |
| Xu, Y | 1 |
| Brown-Jermyn, D | 1 |
| Ascherio, A | 1 |
| Dluzen, DE | 1 |
| Serrats, J | 1 |
| Mengod, G | 1 |
| Cortés, R | 1 |
| Aguilar, E | 1 |
| Xie, X | 1 |
| Ramkumar, V | 1 |
| Toth, LA | 1 |
| Prat, G | 1 |
| Robledo, P | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Jané, F | 1 |
| Casas, M | 1 |
| Staal, R | 1 |
| Xu, YH | 2 |
| Beilstein, M | 1 |
| Sonsalla, PK | 1 |
| Gevaerd, MS | 1 |
| Silveira, R | 1 |
4 reviews available for caffeine and Parkinsonian Disorders
| Article | Year |
|---|---|
Life style and Parkinson's disease.
Topics: Caffeine; Exercise; Humans; Life Style; Parkinson Disease; Parkinsonian Disorders | 2022 |
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian | 2002 |
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A1 Receptor Antagonists; Adenosine A2 Recept | 2003 |
Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation.
Topics: Adenosine; Animals; Behavior, Animal; Caffeine; Corpus Striatum; Dopamine; Humans; Locomotion; Model | 2007 |
26 other studies available for caffeine and Parkinsonian Disorders
| Article | Year |
|---|---|
Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Caffeine; Drug Synergism; Edaravone; Lip | 2019 |
Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
Topics: Caffeine; Humans; Metabolome; Multiple System Atrophy; Parkinsonian Disorders; Supranuclear Palsy, P | 2020 |
Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caffeine; Dopa | 2020 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response | 2015 |
Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism.
Topics: Animals; Caffeine; Fluorescence Resonance Energy Transfer; HEK293 Cells; Humans; Mice; Parkinsonian | 2014 |
Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Caffeine; Cell Survival; Drug Evaluation, Preclinica | 2015 |
Mechanism of Nanotization-Mediated Improvement in the Efficacy of Caffeine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Active Transport, Cell Nucleus; Animals; Biological Tr | 2015 |
Coffee as an anti-parkinsonian agent: a case report.
Topics: Aged, 80 and over; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Coffee; Disord | 2008 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease M | 2009 |
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 C | 2009 |
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; | 2009 |
Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
Topics: Adenosine A2 Receptor Agonists; Animals; Apoptosis; Caffeine; Cells, Cultured; Encephalitis; Female; | 2010 |
Improvement of postural adjustment steps in hemiparkinsonian rats chronically treated with caffeine is mediated by concurrent blockade of A1 and A2A adenosine receptors.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; | 2010 |
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combin | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; D | 2012 |
Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats.
Topics: Animals; Caffeine; Catalepsy; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Dru | 2013 |
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
Topics: Animals; Caffeine; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purinergic P1 Receptor An | 2002 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caff | 2003 |
Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Calcium; Cell Size; | 2004 |
Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Calorimetry; Humans; Models, Molecu | 2005 |
Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 CY | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; | 2006 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug | 2000 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |
Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Caffeine; Central Nervous | 2001 |
Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Dopamine; Dopamine A | 2002 |